One such mechanism was demonstrated by Schonnerr et al., showing that anaplastic lymphoma kinase (ALK) was involved in initiating the transcription of MYCN in neuroblastoma cells [15], providing a potential therapeutic path to block the oncogenic function of MYCN. The gene discussed is ALK; the disease is neuroblastoma.